Vij M, Puri Y, Rammohan A, G G, Rajalingam R, Kaliamoorthy I, et al. Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review. World J Gastrointest Oncol. 2022 Mar 15. 14 (3):607-627. [QxMD MEDLINE Link]. [Full Text].
Smits NJ, Reeders JW. Imaging and staging of biliopancreatic malignancy: role of ultrasound. Ann Oncol. 1999. 10 Suppl 4:20-4. [QxMD MEDLINE Link].
Keane MG, Pereira SP. Improving detection and treatment of liver cancer. Practitioner. 2013 Jul-Aug. 257 (1763):21-6, 2-3. [QxMD MEDLINE Link].
Saurin JC, Joly-Pharaboz MO, Pernas P, Henry L, Ponchon T, Madjar JJ. Detection of Ki-ras gene point mutations in bile specimens for the differential diagnosis of malignant and benign biliary strictures. Gut. 2000 Sep. 47 (3):357-61. [QxMD MEDLINE Link]. [Full Text].
Rijken AM, Offerhaus GJ, Polak MM, Gouma DJ, van Gulik TM. p53 expression as a prognostic determinant in resected distal bile duct carcinoma. Eur J Surg Oncol. 1999 Jun. 25 (3):297-301. [QxMD MEDLINE Link].
Nakanuma Y, Miyata T, Uchida T. Latest advances in the pathological understanding of cholangiocarcinomas. Expert Rev Gastroenterol Hepatol. 2016. 10 (1):113-27. [QxMD MEDLINE Link].
Elfaki DH, Gossard AA, Lindor KD. Cholangiocarcinoma: expanding the spectrum of risk factors. J Gastrointest Cancer. 2008. 39 (1-4):114-7. [QxMD MEDLINE Link].
Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999. 10 Suppl 4:308-11. [QxMD MEDLINE Link].
Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013 Dec. 45 (12):1474-8. [QxMD MEDLINE Link].
Petrick JL, Yang B, Altekruse SF, Van Dyke AL, Koshiol J, Graubard BI, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare. PLoS One. 2017. 12 (10):e0186643. [QxMD MEDLINE Link]. [Full Text].
Doussot A, Groot-Koerkamp B, Wiggers JK, Chou J, Gonen M, DeMatteo RP, et al. Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models. J Am Coll Surg. 2015 Aug. 221 (2):452-61. [QxMD MEDLINE Link].
Freeny PC. Computed tomography in the diagnosis and staging of cholangiocarcinoma and pancreatic carcinoma. Ann Oncol. 1999. 10 Suppl 4:12-7. [QxMD MEDLINE Link].
Lee DH, Kim B, Lee JM, Lee ES, Choi MH, Kim H. Multidetector CT of Extrahepatic Bile Duct Cancer: Diagnostic Performance of Tumor Resectability and Interreader Agreement. Radiology. 2022 Apr 12. 212132. [QxMD MEDLINE Link].
Tani K, Kubota Y, Yamaguchi T, Kitagawa S, Katoh T, Seki T, et al. MR imaging of peripheral cholangiocarcinoma. J Comput Assist Tomogr. 1991 Nov-Dec. 15 (6):975-8. [QxMD MEDLINE Link].
Kim HJ, Lee JM, Kim SH, Han JK, Lee JY, Choi JY, et al. Evaluation of the longitudinal tumor extent of bile duct cancer: value of adding gadolinium-enhanced dynamic imaging to unenhanced images and magnetic resonance cholangiography. J Comput Assist Tomogr. 2007 May-Jun. 31 (3):469-74. [QxMD MEDLINE Link].
Hänninen EL, Pech M, Jonas S, Ricke J, Thelen A, Langrehr J, et al. Magnetic resonance imaging including magnetic resonance cholangiopancreatography for tumor localization and therapy planning in malignant hilar obstructions. Acta Radiol. 2005 Aug. 46 (5):462-70. [QxMD MEDLINE Link].
Sakai Y, Tsuyuguchi T, Tsuchiya S, Fukuda Y, Miyakawa K, Sugiyama H, et al. Clinical utility of peroral cholangioscopy for mucin-producing bile duct tumor. Hepatogastroenterology. 2008 Sep-Oct. 55 (86-87):1509-12. [QxMD MEDLINE Link].
Han NY, Kim JY, Kim MJ, Park BJ, Sung DJ, Sim KC, et al. Validation of Feasibility of Magnetic Resonance Imaging for the Measurement of Depth of Tumor Invasion in Distal Bile Duct Cancer According to the New American Joint Committee on Cancer Staging System. Acad Radiol. 2017 Dec. 24 (12):1526-1534. [QxMD MEDLINE Link].
Choi JH, Lee SK. Percutaneous transhepatic cholangioscopy: does its role still exist?. Clin Endosc. 2013 Sep. 46 (5):529-36. [QxMD MEDLINE Link]. [Full Text].
Rumalla A, Baron TH. Evaluation and endoscopic palliation of cholangiocarcinoma. Management of cholangiocarcinoma. Dig Dis. 1999. 17 (4):194-200. [QxMD MEDLINE Link].
Desa LA, Akosa AB, Lazzara S, Domizio P, Krausz T, Benjamin IS. Cytodiagnosis in the management of extrahepatic biliary stricture. Gut. 1991 Oct. 32 (10):1188-91. [QxMD MEDLINE Link]. [Full Text].
Furmanczyk PS, Grieco VS, Agoff SN. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels. Am J Clin Pathol. 2005 Sep. 124 (3):355-60. [QxMD MEDLINE Link]. [Full Text].
Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol. 1999. 10 Suppl 4:145-9. [QxMD MEDLINE Link].
[Guideline] NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 1.2022. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf. March 29, 2022; Accessed: April 11, 2022.
Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology. 2000 May-Jun. 47 (33):644-9. [QxMD MEDLINE Link].
Oh D, Lim DH, Heo JS, Choi SH, Choi DW, Ahn YC, et al. The role of adjuvant radiotherapy in microscopic tumor control after extrahepatic bile duct cancer surgery. Am J Clin Oncol. 2007 Feb. 30 (1):21-5. [QxMD MEDLINE Link].
Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg. 1995 Jun. 221 (6):788-97; discussion 797-8. [QxMD MEDLINE Link]. [Full Text].
Ma KW, Cheung TT, Leung B, She BWH, Chok KSH, Chan ACY, et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis. Medicine (Baltimore). 2019 Feb. 98 (5):e14013. [QxMD MEDLINE Link]. [Full Text].
Ferrero A, Lo Tesoriere R, Viganò L, Caggiano L, Sgotto E, Capussotti L. Preoperative biliary drainage increases infectious complications after hepatectomy for proximal bile duct tumor obstruction. World J Surg. 2009 Feb. 33 (2):318-25. [QxMD MEDLINE Link].
Gerhards MF, Gonzalez DG, ten Hoopen-Neumann H, van Gulik TM, de Wit LT, Gouma DJ. Prevention of implantation metastases after resection of proximal bile duct tumours with pre-operative low dose radiation therapy. Eur J Surg Oncol. 2000 Aug. 26 (5):480-5. [QxMD MEDLINE Link].
Ortner MA. Photodynamic therapy of cholangiocarcinoma cancer. Gastrointest Endosc Clin N Am. 2000 Jul. 10 (3):481-6. [QxMD MEDLINE Link].
Nanashima A, Hiyoshi M, Imamura N, Hamada T, Nishida T, Kawakami H, et al. Two cases of bile duct carcinoma patients who underwent the photodynamic therapy using talaporfin sodium (Laserphyrin®). Clin J Gastroenterol. 2020 Feb. 13 (1):102-109. [QxMD MEDLINE Link].
Smith I, Kahaleh M. Biliary Tumor Ablation with Photodynamic Therapy and Radiofrequency Ablation. Gastrointest Endosc Clin N Am. 2015 Oct. 25 (4):793-804. [QxMD MEDLINE Link].
Buerlein RCD, Wang AY. Endoscopic Retrograde Cholangiopancreatography-Guided Ablation for Cholangiocarcinoma. Gastrointest Endosc Clin N Am. 2019 Apr. 29 (2):351-367. [QxMD MEDLINE Link].
Jeyarajah DR, Klintmalm GB. Is liver transplantation indicated for cholangiocarcinoma?. J Hepatobiliary Pancreat Surg. 1998. 5 (1):48-51. [QxMD MEDLINE Link].
Kawashima H, Ohno E, Ishikawa T, Mizutani Y, Iida T, Yamamura T, et al. Endoscopic management of perihilar cholangiocarcinoma. Dig Endosc. 2022 Apr 4. [QxMD MEDLINE Link].
Kawamoto H, Ishida E, Okamoto Y, Okada H, Sakaguchi K, Nakagawa M, et al. Evaluation of covered metallic stents in malignant biliary stenosis--prominent effectiveness in gallbladder carcinoma. Hepatogastroenterology. 2005 Sep-Oct. 52 (65):1351-6. [QxMD MEDLINE Link].
Saleem A, Leggett CL, Murad MH, Baron TH. Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc. 2011 Aug. 74 (2):321-327.e1-3. [QxMD MEDLINE Link].
Schinzari G, Rossi E, Mambella G, Strippoli A, Cangiano R, Mutignani M, et al. First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) Versus 5-FU/LV (de Gramont Regimen). Anticancer Res. 2017 Sep. 37 (9):5193-5197. [QxMD MEDLINE Link]. [Full Text].
Jung CFM, Lavole J, Barret M, Abou Ali E, Palmieri LJ, Dermine S, et al. Local Therapy in Advanced Cholangiocarcinoma: A Review of Current Endoscopic, Medical, and Oncologic Treatment Options. Oncology. 2019. 97 (4):191-201. [QxMD MEDLINE Link].
Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 May. 21 (5):671-684. [QxMD MEDLINE Link].
Xia T, Li K, Niu N, Shao Y, Ding D, Thomas DL, et al. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. J Hematol Oncol. 2022 Mar 28. 15 (1):37. [QxMD MEDLINE Link]. [Full Text].
Deng M, Li S, Wang Q, Zhao R, Zou J, Lin W, et al. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Ann Med. 2022 Dec. 54 (1):803-811. [QxMD MEDLINE Link]. [Full Text].
Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg. 1999 Nov. 230 (5):663-71. [QxMD MEDLINE Link]. [Full Text].
Havlik R, Sbisà E, Tullo A, Kelly MD, Mitry RR, Jiao LR, et al. Results of resection for hilar cholangiocarcinoma with analysis of prognostic factors. Hepatogastroenterology. 2000 Jul-Aug. 47 (34):927-31. [QxMD MEDLINE Link].
Levi Sandri GB, Spoletini G, Mascianà G, Colasanti M, Lepiane P, Vennarecci G, et al. The role of minimally invasive surgery in the treatment of cholangiocarcinoma. Eur J Surg Oncol. 2017 Sep. 43 (9):1617-1621. [QxMD MEDLINE Link].